Navigation Links
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Date:6/24/2008

of 2008, with initial data expected shortly thereafter.

About AGENDA

AGENDA is a global Phase 3, randomized, double-blind trial in patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from an antecedent randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood. Analysis of those efficacy outcomes in GM301, which were observed in 274 patients, showed the following results:

Hazard

Endpoint Genasense/DTIC DTIC Ratio P

Overall response 20.8% 7.2% 0.002

Durable response 10.7% 2.4% 0.007

Progression-free 3.6 mos. 1.6 mos. 0.58 < 0.0001

survival, median

Overall survival, 12.3 mos. 9.9 mos. 0.64 0.0009

median

A scientific article that describes efficacy and safety results from GM301 can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1

About the EADO

The EADO is an independent non-profit organization dedicated to the promotion, coordination, and improvement of clinical and laboratory research activities in the field of skin cancer. The organization has an European and international membership of dermatologists, oncologists and clinical as well as basic research scientists interested in the field of dermato-oncology. EADO provides leadership by formulating and disseminating quality standards and
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
2. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Genta Receives Key Patent Related to Oral Gallium Compound G4544
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Genta Clinical Programs Featured at American Society of Hematology Meeting
11. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com announces ... its catalogue: Asia - Pacific Minimally ... http://www.reportlinker.com/p02353212/Asia---Pacific-Minimally-Invasive-Surgery-Spinal-Device-Market.html The growth rate of the ... device market will remain at double-digit levels throughout the ... as the future of this field. The ...
(Date:9/2/2014)... , Sept. 2, 2014 The Pharmaceutical Care ... benefit managers (PBMs), today filed a lawsuit in ... new Iowa law that restricts ... for the state,s employers and consumers.  ... by severely restricting the use of Maximum Allowable Cost ...
(Date:9/2/2014)... BARCELONA , Spanien und CALGARY, Alberta ... Vorgestellt in der "State of the ... Kardiologenverbandes 2014    Resverlogix Corp. (TSX: RVX) ... of Medical Affairs bei Resverlogix, beim Kongress des europäischen ... Spanien, einen Vortrag gehalten hat. In seinem Vortrag mit ...
Breaking Medicine Technology:Asia - Pacific Minimally Invasive Surgery Spinal Device Market 2Asia - Pacific Minimally Invasive Surgery Spinal Device Market 3Asia - Pacific Minimally Invasive Surgery Spinal Device Market 4Asia - Pacific Minimally Invasive Surgery Spinal Device Market 5Asia - Pacific Minimally Invasive Surgery Spinal Device Market 6Asia - Pacific Minimally Invasive Surgery Spinal Device Market 7Asia - Pacific Minimally Invasive Surgery Spinal Device Market 8Asia - Pacific Minimally Invasive Surgery Spinal Device Market 9Asia - Pacific Minimally Invasive Surgery Spinal Device Market 10Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6
... DIEGO, May 4, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 2011 financial results after the NASDAQ Global Select Market closes ... Arena,s President and Chief Executive Officer, will host a conference ... Pacific Time) to discuss the financial results for the first ...
... ULURU Inc. (NYSE AMEX: ULU) ... with the U.S. Food and Drug Administration to obtain ... containing wound care products represent a growing segment of ... and contributes to new tissue development. Collagen dressings encourage ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10 3ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen 2
(Date:9/2/2014)... (HealthDay News) -- Complications are rare among breast ... new study indicates. However, the researchers did ... a slightly higher risk for certain complications than ... than 18,000 breast cancer patients who had a ... breast reconstruction and were followed for 30 days ...
(Date:9/2/2014)... can lay the groundwork for their own spread throughout ... send out tumor-welcoming signals, according to a new report ... 2 issue of Nature Communications , the researchers ... of so-called signaling molecules released by breast cancer cells. ... lungs and lymph nodes to produce proteins called CCL5 ...
(Date:9/2/2014)... Australia (PRWEB) September 03, 2014 Operators ... attend to millions of people annually, arranging care and ... not-for-profit and private enterprises are expected to derive $39.4 ... funding, donations and private income. Over the five years ... an annualised rate of 6.6%, including growth of 4.1% ...
(Date:9/2/2014)... (HealthDay News) -- Melatonin supplements did not reduce delirium ... new study found. Many older hospital patients experience ... disruption of their normal sleep-wake cycle. A lack of ... to delirium, but there has been little research into ... study included 378 patients, average age 84, who had ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... As the Ebola outbreak continues to overwhelm health-care workers ... United States and the United Nations called on Tuesday ... outbreak of the often-fatal virus. Dr. Thomas Frieden, ... Prevention, said that without a greater global commitment in ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... metabolic syndrome in strained unions, study finds , , THURSDAY, March ... unhappy marriage may be greater for women than men, a ... "strained" unions, those marked by arguing and being angry, were ... in the contentious relationships were more likely to develop high ...
... to Educate Americans on Value of Occupational Therapy and Important Role ... ... (Vocus) March 5, 2009 -- The American Occupational Therapy Association (AOTA) ... public about the scope and value of what experts are predicting ...
... 5 Medifast, Inc. (NYSE: MED ), ... today announced the appointment of John P. Daniels and ... Directors. With the addition of Mr. Daniels and ... comprised of fourteen members, ten of which are classified ...
... ANTONIO, March 5 A plentiful, inexpensive, topical compound ... Middle Eastern and African leishmaniasis as is the standard ... one of the findings of a research team from ... Thomas Jefferson University and led by Reza ...
... March 5 CorMatrix Cardiovascular, Inc., an Atlanta-based ... matrix (ECM Technology) biomaterial devices that harness the ... announced today that it has begun its expansion ... CorMatrix(R) ECM Technology(TM) in a patient undergoing cardiac ...
... Company suspends patient enrollment and contract manufacturing, ... 5 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (BMR.TSX), today announced ... existing cash resources. The plan is in response to ... Company,s ongoing evaluation of strategic alternatives. , As announced ...
Cached Medicine News:Health News:Bad Marriages Harder on Women's Health 2Health News:Bad Marriages Harder on Women's Health 3Health News:Nearing Centennial, Occupational Therapy Profession Launches New Brand 2Health News:Nearing Centennial, Occupational Therapy Profession Launches New Brand 3Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 2Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 3Health News:Medifast, Inc. Announces Appointment of Two Additional Independent Board Members 4Health News:The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection 2Health News:CorMatrix Cardiovascular Announces First European Implants of CorMatrix(R) ECM Technology(TM) 2Health News:Bradmer implements cash conservation plan 2Health News:Bradmer implements cash conservation plan 3
... Available in 6 popular colors ... Wide crescent shape to accommodate wheel ... exam. Strong, smooth and quiet elctro-mechanical ... top. 2 Position programmable memory Patient ...
Strong, 14 gauge steel construction for lasting quality. Locking wheels for use on carpet or tile flooring. Whisper quiet up/down movement. Easy cleaning deluxe laminated top. Three year warranty....
...
... construction for lifelong quality. Sealed hydraulic system ... movement. Soft, contoured cushions with heavy-duty upholstery ... slit lamp arm for easy, smooth, and ... lamp arm for easy access to children ...
Medicine Products: